Copyright
©The Author(s) 2022. Published by Baishideng Publishing Group Inc. All rights reserved.
World J Gastrointest Oncol. Aug 15, 2022; 14(8): 1528-1539
Published online Aug 15, 2022. doi: 10.4251/wjgo.v14.i8.1528
Published online Aug 15, 2022. doi: 10.4251/wjgo.v14.i8.1528
Profiling of gene fusion involving targetable genes in Chinese gastric cancer
Zhen-Hua Liu, Department of Medical Oncology, Fujian Medical University, Fuzhou 350001, Fujian Province, China
Bo-Wen Zhu, Min Shi, Yu-Rong Qu, Hong-Ling Yuan, Wei Li, Dan-Dan Zhao, Bao-Ming Wang, Chun-Yang Wang, Medical Center, Genetron Health (Beijing) Technology, Co. Ltd., Beijing 102200, China
Xun-Jun He, Department of Genetics and Genomic Medicine, Zhejiang Provincial People’s Hospital, Hangzhou 310000, Zhejiang Province, China
Xun-Jun He, Zheng-Chuang Liu, Hou-Quan Tao, Key Laboratory of Gastroenterology of Zhejiang Province, Zhejiang Provincial People’s Hospital, Hangzhou 310000, Zhejiang Province, China
Jie Ma, Department of Pathology, Zhejiang Provincial People's Hospital, Hangzhou 310000, Zhejiang Province, China
Zheng-Chuang Liu, Hou-Quan Tao, Department of Gastroenterology of Zhejiang Province, Zhejiang Provincial People’s Hospital, Hangzhou 310000, Zhejiang Province, China
Tong-Hui Ma, Department of Translational Medicine, Genetron Health (Beijing) Technology, Co. Ltd., Beijing 102200, China
Author contributions: Liu ZH and Ma TH designed the study and reviewed the manuscript; Liu ZH, Zhu BW, Shi M analyzed the clinical and gene fusions data and wrote the manuscript; He XJ, Ma J, Liu ZC, and Tao HQ provided clinical advice; Yuan HL, Li W, Zhao DD, Wang BM, and Wang CY reviewed the manuscript and provided advice; All authors have read and approved the final manuscript.
Institutional review board statement: The study was reviewed and approved by the Fujian Provincial Hospital, Institutional Review Board (Approval No. K2022-03-101).
Informed consent statement: All study participants or their legal guardian provided informed written consent about personal and medical data collection prior to study enrolment.
Conflict-of-interest statement: All the authors report no relevant conflicts of interest for this article.
Data sharing statement: No additional data are available.
Open-Access: This article is an open-access article that was selected by an in-house editor and fully peer-reviewed by external reviewers. It is distributed in accordance with the Creative Commons Attribution NonCommercial (CC BY-NC 4.0) license, which permits others to distribute, remix, adapt, build upon this work non-commercially, and license their derivative works on different terms, provided the original work is properly cited and the use is non-commercial. See: https://creativecommons.org/Licenses/by-nc/4.0/
Corresponding author: Tong-Hui Ma, PhD, Director, Department of Translational Medicine, Genetron Health (Beijing) Technology, Co. Ltd., 1-2/F, Building 11, Zone 1, 8 Life Science Parkway, Changping District, Beijing 102200, China. tonghuima0818@sina.com
Received: March 30, 2022
Peer-review started: March 30, 2022
First decision: June 2, 2022
Revised: June 14, 2022
Accepted: July 19, 2022
Article in press: July 19, 2022
Published online: August 15, 2022
Peer-review started: March 30, 2022
First decision: June 2, 2022
Revised: June 14, 2022
Accepted: July 19, 2022
Article in press: July 19, 2022
Published online: August 15, 2022
Core Tip
Core Tip: The proportion of patients with gene fusions in Chinese patients with gastric cancer (GC) has not yet been characterized. In our analysis, we found that 1.68% of such patients harbor fusions involving targetable genes. Moreover, these fusion genes were enriched in patients with ERBB2 amplification. Our study indicates that gene fusion detection may provide a novel approach for GC therapy.